SecBot SecBot

VSTM

Verastem, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. MA· CIK 0001526119 Biotech & Drug Discovery
$10.00 −0.04 (−0.40%)
Oct 26 4:00 PM ET · prev $10.04
Market cap
$1.2B
Small cap
Consensus
Buy
94% Buy or better · 16 analysts
Median target
$18.00
+80% · range $12.00–24.00
Next earnings
Nov 2
in 6 days
1 year
+14.7%
from $8.72 · Oct 27
30 days
+28.7%
from $7.77
52-week range
$3.45–10.64
−6% from high · low Jun 25
Avg volume 20D
5.65M
Oct 14 spike 33.75M
Short interest
🔒 Subscribers only
Insider net
−$497.0K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 4 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 2, 2026
Strongest BULLISH Verastem reported preliminary Q3 2026 net product revenue of ~$23.9-24.1M (vs $11.2M YoY), announced CEO Dan…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $497.0K.

  • InstitutionsBULLISH

    Q2 2026: 33 added (0 new), 10 trimmed or exited.

  • AnalystsBULLISH

    15 of 16 rate it Buy or better. Every target is above the price.

  • TrendUPTREND

    26% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD9,192,447$35.1M
STATE STREET CORPADD5,133,859$19.6M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED3,266,870$12.5M
GOLDMAN SACHS GROUP INCADD2,721,178$10.4M
BAKER BROS. ADVISORS LPDOUBLED2,499,338$9.5M
BALYASNY ASSET MANAGEMENT L.P.DOUBLED1,686,575$6.4M
Pinnacle Financial Partners, Inc.DOUBLED1,086,440$4.2M
BANK OF AMERICA CORP /DE/DOUBLED889,975$3.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 94% rate it Buy or better
Strong Buy6Buy9Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +80%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 19, 2026BTIG
REITERATE
REITERATEBuy
Oct 16, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Oct 15, 2026Jefferies
MAINTAIN
MAINTAINBuy
Oct 15, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Oct 15, 2026BTIG
MAINTAIN
MAINTAINBuy
Oct 8, 2026BTIG
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$497.0K
sold · 2 insiders
DateInsiderTypeValue
Oct 1, 2026
Paterson Dan
President and CEO
SELL$353.0K
Oct 1, 2026
Calkins Daniel
Chief Financial Officer
SELL$20.5K
Sep 30, 2026
Paterson Dan
President and CEO
AWARD106,893 sh
Sep 30, 2026
Calkins Daniel
Chief Financial Officer
AWARD8,333 sh
Sep 21, 2026
Calkins Daniel
Chief Financial Officer
SELL$423.50
Aug 3, 2026
Paterson Dan
President and CEO
SELL$7.6K
Jun 22, 2026
Calkins Daniel
Chief Financial Officer
SELL$16.9K
Jun 22, 2026
Paterson Dan
President and CEO
SELL$87.2K

Earnings setup

Estimates
Nov 2
reports in 6 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 14, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Verastem priced a public offering of 30,937,500 shares of common stock at $8.00/share and pre-funded warrants to…
8-K — Impact 6/10
Oct 14, 2026 SEC
Verastem priced a $250M underwritten public offering of 30,937,500 common shares at $8.00/share (a ~7.4% premium to…
424B5 — Impact 6/10
Oct 14, 2026 SEC
Verastem is conducting a dilutive underwritten public offering of common stock and pre-funded warrants, with pricing…
424B5 — Impact 6/10
Oct 14, 2026 Trading halt
Halt Resumed: VSTM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-14T13:42:27.000Z | Resumed 2026-10-14T13:47:27.000Z
Oct 1, 2026 Insider
Paterson Dan sold 44,121 shares
President and CEO @ $8.00 ($353.0K)
Oct 1, 2026 Insider
Calkins Daniel sold 2,566 shares
Chief Financial Officer @ $8.00 ($20.5K)
Sep 30, 2026 Insider
Paterson Dan was granted 106,893 shares
President and CEO
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
9,192,447 shares ($35.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
VSTM Q3 2026 Earnings Scheduled — 2026-11-02
Recent
Oct 14, 2026
Trading halt
Halt Resumed: VSTM — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-10-14T13:42:27.000Z | Resumed 2026-10-14T13:47:27.000Z
Oct 14, 2026
Trading halt
Trading Halt: VSTM — LUDP (Volatility Trading Pause)
Verastem, Inc. | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 8, 2026
Trial readout
Results Pending: avutometinib (VS-6766) and adagrasib (Phase 2) — Completed 85d ago
Trial: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Sponsor: Verastem, Inc. Phase: Phase 2 | Completed: 2026-06-15…
Sep 8, 2026
Trial readout
Results Pending: avutometinib (VS-6766) and adagrasib (Phase 2) — Completed 85d ago
Trial: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Sponsor: Verastem, Inc. Phase: Phase 2 | Completed: 2026-06-15…
Aug 25, 2026
Trial readout
Results Pending: avutometinib (VS-6766) and adagrasib (Phase 2) — Completed 71d ago
Trial: Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Sponsor: Verastem, Inc. Phase: Phase 2 | Completed: 2026-06-15…

SecBot reports

12 filings · 4 bullish · 4 bearish · 4 neutral
All VSTM filing & press-release reports (12)